intranasal influenza antibody CR9114
Jump to navigation
Jump to search
Indications
- investigational prevention of influenza A & influenza B
Dosage
- intranasal delivery
Mechanism of action
- influenza virus hemagglutinin-specific antibody
More general terms
References
- ↑ Beukenhorst AL, Rogiers R, Rice KL et al Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114. Sci Transl Med. 2026 Feb 4;18(835):eadz1580. PMID: https://pubmed.ncbi.nlm.nih.gov/41637527 Clinical Trial. https://www.science.org/doi/10.1126/scitranslmed.adz1580